吉林大学学报(医学版) ›› 2013, Vol. 39 ›› Issue (1): 122-127.doi: 10.7694/jldxyxb20130128

• 基础研究 • 上一篇    下一篇

吉西他滨联合顺铂方案在非小细胞肺癌术后辅助化疗中的疗效及
影响因素分析

李恩喜,尹威民,王 旭,马克威   

  1. 吉林大学第一医院肿瘤中心,吉林 长春 130021
  • 收稿日期:2012-08-13 出版日期:2013-01-28 发布日期:2013-01-30
  • 通讯作者: 马克威(Tel:0431-88782720,E-mail:kwma2006@yahoo.com.cn) E-mail:kwma2006@yahoo.com.cn
  • 作者简介:李恩喜(1986-),女,山西省翼城县人,在读医学硕士,主要从事肿瘤的 分子靶向治疗研究。
  • 基金资助:

    国家自然科学基金资助课题(30671091)

Efficacy and influencing factor analysis of GP regimen
 in postoperative adjuvant chemotherapy for
 non-small-cell lung cancer


LI En-xi,YIN Wei-min,WANG Xu,MA Ke-wei   

  1. Tumor Center,First Hospital,Jilin University,Changchun 130021,
    China
  • Received:2012-08-13 Online:2013-01-28 Published:2013-01-30

摘要: 目的: 观察术后接受吉西他滨联合顺铂(GP)方案辅助化疗的非小细胞肺癌(NSCL
C)患者的近期疗效,探讨影响疗效的因素并分析其不良反应。方法: 回顾性分析68例NSCLC术后且行GP方案辅助
化疗患者的临床资料。采用Kaplan-Meier法绘制无病生存曲线,不同亚组间用Log-rank时
序检验;单因素、多因素分析采用COX比例风险回归模型。结果: 本组患者整体中位无复发生
存时间为33.7个月,随访1年以上的患者56例,1年无病生存率为83.9%,随访2年以上
的患者25例,2年无病生存率为72.0%。单因素分析,临床分期(P<0.05)、病理类型(P<
0.05)、分化程度(P<0.05)是影响近期疗效的因素;多因素分析,临床分期(P<0.05)、分化程
度(P<0.05)是影响近期疗效的独立因素。主要的不良反应为Ⅲ-Ⅳ度骨髓抑制[包括粒细胞减少(
33.9%),白细胞减少(20.6%),贫血(4.4%),血小板减少(4.4%)]和Ⅲ-Ⅳ度恶心及呕
吐(10.3%)。结论:GP方案在NSCLC患者术后辅助化疗中的1、2年疾病控制率高,不良反应
轻;其中临床分期及分化程度是NSCLC患者术后接受GP方案辅助化疗近期疗效的影响因素。

关键词:  , 癌,非小细胞肺, 抗肿瘤联合化疗方案, 吉西他滨, 顺铂, 中位无复发
生存时间,
无病生存率

Abstract: Objective  To observe the short-term efficacy of GP regimen in adjuvant chemotherapy in patients with non-small-cell lung cancer,and to study t
he factors influencing efficacy and analyze the adverse reactions.
Methods  Clinical data of 68 NSCLC patients received postoperative adjuvant chemotherapy of GP regimen was  retrospectively analyzed.Kaplan-Meier method was used to draw the disease-free survival curve.Log-rank time series analysis was used between different subgroups;C
OX proportional hazards model was used for the univariate and multivariate analyses.
Results  Of all the 68 cases,the median recurrence-free survival time was 33.7 months,56 cases were followed up more than one year,and one year disease-free survival rate was 83.9%;25 cases were followed up more than two years,and
two-year disease-free survival was 72.0%.Univariate analysis suggested that clinical stage(P<0.05),pathological type(P<0.05),degree of differentiation(P<0.05) significantly influenced the short-term efficacy. Multivariate analysis suggested that clinical stage(P<0.05),degree of differentiation(P<0.05) were thei
ndependent factors of the short-term efficacy.The major adverse reactions were stage 3 to 4 myelo-suppression including neutropenia(33.9%),granulocytopenia(20.6%),anemia(4.4%),and thrombocytopenia(4.4%),and  stage 3 to 4 nausea and vomiting(10.3%).
Conclusion The GP regimen is feasible,well-tolerated with a high disease control rate in one or two years in the adjuvant chemotherapy;clinical stage
and degree of differentiation are the independent factors of the short-term efficacy.

Key words: cancer,non-small cell lung, antineoplastic combined chemotherapy protocols, gemcitabine, cisplatin, median recurrence-freesurvival time, disease-free survival rate

中图分类号: 

  •